what this node claims
AlphaFold metrics / KL
Model-quality receipt for the fold. It is not biological validation.
vertical proof spine
evidence / risk instrument
54%
low debt pressure
21%
89%structurestrong
pLDDT 89.09
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine
proof completeness
33% missing target, candidate, finding, export- 01 target
- 02 fold
- 03 alphafold metric
- 04 candidate
- 05 finding
- 06 export
Metrics and receipt inputs
- confidence band
- confident
- confidence pct
- 89.09
- coverage context
- missing or not linked
- interpretation
- usable fold context with explicit model-confidence limits
- pae context
- missing or not linked
- plddt avg
- 89.09
- sequence length
- 0
AlphaFold metrics visual
Confident backbone model
1012 residues / min 28.19 / max 98.81 / source alphafold db
Very high
72.9%
738 residues / >=90
Confident
17.5%
177 residues / 70-89
Low
4.1%
41 residues / 50-69
Very low
5.5%
56 residues / <50
usable fold context with explicit model-confidence limits
Near-complete coverage / observed 1012 of 1012 residues.
- residues 1-33 / mean 37.0
- residues 97-119 / mean 41.65
- residues 957-979 / mean 56.7
- residues 1007-1012 / mean 55.1
proof debt register
21%
Visible limits, not hidden cleanup.
Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.